Department of Nuclear Medicine

The Department of Nuclear Medicine specializes in the utilization of radioactive materials (radioisotopes) for diagnostic tests and treatments. Nuclear medicine imaging is a unique and non-invasive approach that provides valuable structural and functional information of organs. The majority of isotopes utilized in Clinical Nuclear Medicine are produced at BARC, Mumbai, with the remainder being imported. Radiopharmaceuticals, which are chemicals labeled with small amounts of isotopes, are used for both diagnosis and treatment purposes.

Radiopharmaceuticals are used for tests and therapy. They are injected into the patient's body or administered as a capsule. After a few minutes/hours/days, the patient is scanned with a Gamma camera or PET-CT scanner to produce detailed images of the body. The radiopharmaceuticals go directly to the organ or diseased tissue being treated in targeted molecular therapy. Safety methods are ensured during every procedure, and the principle of ALARA radiation exposure is followed.

Diagnostic Services in Nuclear Cardiology

Stress /Rest myocardial perfusion SPECT

Radiopharmaceutical: 99mTc- MIBI (8mCi / 24mCi) 99mTc- Myoview

INDICATIONS:

1. Detect coronary artery disease.
2. Evaluate physiologic significance or sequelae of known or suspected CAD
3. Viability of dysfunctional myocardium
4. Ventricular function (using gated images).
5. Monitor the effects of treatment, including revascularization.
6. Stratify risk

Gated RNV/ first pass RNA

Radiopharmaceutical: 99mTc-labeled RBC.

INDICATIONS:

First-pass cardiac scans:
1. Calculate left and right ventricular ejection fractions.
2. Assess wall motion abnormalities.
3. Quantitate left-to-right cardiac shunts.

Gated cardiac blood pool imaging:
1. Focal and global wall motion abnormalities.
2. Ventricular function:
3. Ejection fraction,
4. Cardiac volumes,
5. Cardiac output,
6. Diastolic function.
7. Cardiotoxic effects of chemotherapy
8. Valvular regurgitation.

Cardiac Amyloidosis Study

Radiopharmaceutical: 99mTcTPP

INDICATIONS:

1. To diagnose and assess the location and extent of cardiac amyloidosis
2. To differentiate between AL and ATTR

PET Cardiac Viability

Radiopharmaceutical: 18FDG & Tc99mMIBI

INDICATIONS:

To identify areas of perfusion-metabolism mismatch, thereby determining the viable myocardium that will benefit from re-vascularisation procedures.

PET cardiac sarcoidosis

Radiopharmaceutical: Tc99m-MIBI & F18-FDG

INDICATIONS:

1. Patients with histologic evidence of extra CS and abnormal screening for CS

2. Patients with an unexplained, new onset of significant conduction system disease

3. Patients with Idiopathic Sustained Ventricular Tachycardia

4. Patients with proven CS

Back

CARDIAC ELECTROPHYSIOLOGY
& PACING
(Cardiology Unit IV) - CMC VELLORE

Treating Abnormal Heart Rhythms

Department of Nuclear Medicine

Diagnostic Services in Nuclear Cardiology

CARDIAC ELECTROPHYSIOLOGY & PACING (Cardiology Unit IV) - CMC VELLORE

Treating Abnormal Heart Rhythms

Department of Nuclear Medicine

Diagnostic Services in Nuclear Cardiology

CARDIAC ELECTROPHYSIOLOGY
& PACING
(Cardiology Unit IV) - CMC VELLORE